Drug intelligence / Profile preview

CY008

Development stage: Preclinical
Lead developer: Shanghai Chaoyang Pharmaceutical
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules

Overview

CY008 is a proteolysis-targeting chimera (PROTAC) being developed by Shanghai Helioson Pharmaceutical for the treatment of autoimmune diseases. As a PROTAC, it is a bifunctional molecule designed to recruit an E3 ubiquitin ligase to a specific target protein, leading to the target's ubiquitination and subsequent degradation by the proteasome. The specific molecular target for CY008 has not been publicly disclosed by the company. It is currently in the early stages of development, categorized as being in the discovery or preclinical phase.

Beyond the preview

Go deeper on CY008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CY008.

Explore the full profile